Bridging Pharmaceutical Challenges and Technology: Innovative Formulation and Analysis of Telmisartan
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2026
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901581232865280 |
|---|---|
| author | Namneet kaur*, Maninder Pal Singh, Anuradha kumari, Gurpreet kaur, Nitka |
| author_facet | Namneet kaur*, Maninder Pal Singh, Anuradha kumari, Gurpreet kaur, Nitka |
| contents | <p class="MsoNormal"><span>Owing to its complex biopharmaceutical properties, telmisartan, a widely prescribed angiotensin II receptor antagonist for the treatment of hypertension and cardiovascular diseases, remains a focus of great interest in pharmaceutical research. Telmisartan is a poorly water-soluble drug with absorption-limited bioavailability due to its dissolution rate-limited absorption, despite its high membrane permeability. Telmisartan poses severe formulation and stability issues as a Biopharmaceutics Classification System (BCS) Class II drug, which restricts its therapeutic potential in the conventional dosage form.In this review, a comprehensive and critical evaluation of the current advances (2020-2025) in telmisartan formulation technologies and analytical methods to overcome these challenges is discussed. Emerging strategies such as solid dispersions, nanocrystals, lipid-based drug delivery systems, cyclodextrin inclusion complexes, polymeric micelles, mesoporous carriers, co-amorphous formulations, and fast-dissolving oral films are described in terms of their efficacy in enhancing solubility, dissolution performance, stability, and patient compliance.At the same time, the use of latest analytical tools like stability-indicating chromatographic methods, LC-MS/MS bioanalysis, solid-state analysis, and green analytical chemistry is critically evaluated. Moreover, the importance of regulatory approaches, stability issues, and Quality by Design (QbD) development approaches is also emphasized in this review. In conclusion, the integration of formulation science and analytical technology is a major driving force in the development of patient-centric, stable, and bioavailable telmisartan dosage forms, and future directions are also discussed in this review</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20228732 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Bridging Pharmaceutical Challenges and Technology: Innovative Formulation and Analysis of Telmisartan Namneet kaur*, Maninder Pal Singh, Anuradha kumari, Gurpreet kaur, Nitka Telmisartan; Poor aqueous solubility; BCS Class II; Advanced drug delivery systems; Nanocrystals; Lipid-based formulations; Solid dispersions; Stability studies; Quality by Design (QbD); Analytical method development <p class="MsoNormal"><span>Owing to its complex biopharmaceutical properties, telmisartan, a widely prescribed angiotensin II receptor antagonist for the treatment of hypertension and cardiovascular diseases, remains a focus of great interest in pharmaceutical research. Telmisartan is a poorly water-soluble drug with absorption-limited bioavailability due to its dissolution rate-limited absorption, despite its high membrane permeability. Telmisartan poses severe formulation and stability issues as a Biopharmaceutics Classification System (BCS) Class II drug, which restricts its therapeutic potential in the conventional dosage form.In this review, a comprehensive and critical evaluation of the current advances (2020-2025) in telmisartan formulation technologies and analytical methods to overcome these challenges is discussed. Emerging strategies such as solid dispersions, nanocrystals, lipid-based drug delivery systems, cyclodextrin inclusion complexes, polymeric micelles, mesoporous carriers, co-amorphous formulations, and fast-dissolving oral films are described in terms of their efficacy in enhancing solubility, dissolution performance, stability, and patient compliance.At the same time, the use of latest analytical tools like stability-indicating chromatographic methods, LC-MS/MS bioanalysis, solid-state analysis, and green analytical chemistry is critically evaluated. Moreover, the importance of regulatory approaches, stability issues, and Quality by Design (QbD) development approaches is also emphasized in this review. In conclusion, the integration of formulation science and analytical technology is a major driving force in the development of patient-centric, stable, and bioavailable telmisartan dosage forms, and future directions are also discussed in this review</span></p> |
| title | Bridging Pharmaceutical Challenges and Technology: Innovative Formulation and Analysis of Telmisartan |
| topic | Telmisartan; Poor aqueous solubility; BCS Class II; Advanced drug delivery systems; Nanocrystals; Lipid-based formulations; Solid dispersions; Stability studies; Quality by Design (QbD); Analytical method development |
| url | https://doi.org/10.5281/zenodo.20228732 |